- Home
- LVTX vs VYNE Comparison
LVTX vs VYNE Comparison
Compare LVTX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- VYNE
- Stock Information
- Founded
- LVTX 2016
- VYNE 2003
- Country
- LVTX Netherlands
- VYNE United States
- Employees
- LVTX N/A
- VYNE N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- VYNE Health Care
- Exchange
- LVTX Nasdaq
- VYNE Nasdaq
- Market Cap
- LVTX 34.2M
- VYNE 35.7M
- IPO Year
- LVTX 2021
- VYNE 2018
- Fundamental
- Price
- LVTX $1.25
- VYNE $1.70
- Analyst Decision
- LVTX Hold
- VYNE Strong Buy
- Analyst Count
- LVTX 3
- VYNE 2
- Target Price
- LVTX $3.17
- VYNE $6.88
- AVG Volume (30 Days)
- LVTX 72.6K
- VYNE 187.0K
- Earning Date
- LVTX 03-28-2025
- VYNE 03-06-2025
- Dividend Yield
- LVTX N/A
- VYNE N/A
- EPS Growth
- LVTX N/A
- VYNE N/A
- EPS
- LVTX N/A
- VYNE N/A
- Revenue
- LVTX $11,982,000.00
- VYNE $501,000.00
- Revenue This Year
- LVTX $16.68
- VYNE N/A
- Revenue Next Year
- LVTX N/A
- VYNE $20.00
- P/E Ratio
- LVTX N/A
- VYNE N/A
- Revenue Growth
- LVTX 77.01
- VYNE 18.16
- 52 Week Low
- LVTX $0.85
- VYNE $1.57
- 52 Week High
- LVTX $3.57
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- LVTX 49.47
- VYNE 31.15
- Support Level
- LVTX $1.20
- VYNE $1.62
- Resistance Level
- LVTX $1.36
- VYNE $1.86
- Average True Range (ATR)
- LVTX 0.08
- VYNE 0.16
- MACD
- LVTX -0.02
- VYNE 0.01
- Stochastic Oscillator
- LVTX 29.41
- VYNE 21.62
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.